{"id":2171,"date":"2015-08-18T11:13:29","date_gmt":"2015-08-18T09:13:29","guid":{"rendered":"https:\/\/blog.uchceu.es\/farmacia\/?p=2171"},"modified":"2020-02-21T15:10:30","modified_gmt":"2020-02-21T14:10:30","slug":"combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves","status":"publish","type":"post","link":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/","title":{"rendered":"Combinaciones de cotrimoxazol y antihipertensivos  (IECA, ARA-II) potencian el riesgo de reacciones adversas graves."},"content":{"rendered":"<p><a href=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-2172 aligncenter\" src=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072-315x236.png\" alt=\"10-07\" width=\"363\" height=\"272\" srcset=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072-315x236.png 315w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png 566w\" sizes=\"auto, (max-width: 363px) 100vw, 363px\" \/><\/a><strong><u>Cotrimoxazol<\/u><\/strong> es un antimicrobiano que pertenece a la familia de las sulfonamidas, siendo una combinaci\u00f3n de trimetoprima y sulfametoxazol.<\/p>\n<p>Los inhibidores de la enzima convertidora de angiotensina <strong><u>(IECAs)<\/u><\/strong> y los antagonistas de los receptores de angiotensina II <strong><em>(ARA II)<\/em><\/strong>, son f\u00e1rmacos utilizados habitualmente para el tratamiento de la hipertensi\u00f3n arterial. Act\u00faan bloqueando a distinto nivel el sistema renina-angiotensina.<\/p>\n<p>En 2014 se public\u00f3 un estudio en el que los pacientes con tratamiento con un IECA o ARA II fallecieron repentinamente en el plazo de 7 d\u00edas tras ser tratados con un antibi\u00f3tico, entre los cuales el cotrimoxazol se asoci\u00f3 a un mayor riesgo de muerte s\u00fabita.<\/p>\n<p><a href=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-2173 alignleft\" src=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10-315x236.jpg\" alt=\"07--10\" width=\"423\" height=\"317\" srcset=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10-315x236.jpg 315w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10-768x576.jpg 768w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10-650x488.jpg 650w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10-696x522.jpg 696w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/07-10.jpg 960w\" sizes=\"auto, (max-width: 423px) 100vw, 423px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Los autores atribuyen este riesgo a una muerte por arritmia no diagnosticada a causa de una hiperpotasemia, y sugieren considerar un antibi\u00f3tico alternativo o limitar la dosis y la duraci\u00f3n del tratamiento con cotrimoxazol en pacientes tratados con un IECAs o un ARA II.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cotrimoxazol es un antimicrobiano que pertenece a la familia de las sulfonamidas, siendo una combinaci\u00f3n de trimetoprima y sulfametoxazol. Los inhibidores de la enzima convertidora de angiotensina (IECAs) y los antagonistas de los receptores de angiotensina II (ARA II), son f\u00e1rmacos utilizados habitualmente para el tratamiento de la hipertensi\u00f3n arterial. Act\u00faan bloqueando a distinto nivel [&hellip;]<\/p>\n","protected":false},"author":362,"featured_media":2172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[35,41,44,47,57],"class_list":{"0":"post-2171","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-divulgacion-cientifica","8":"tag-farmacologia","9":"tag-historias-de-medicamentos","10":"tag-innovaciones-terapeuticas","11":"tag-laboratorio","12":"tag-salud-publica"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.\" \/>\n<meta property=\"og:description\" content=\"Cotrimoxazol es un antimicrobiano que pertenece a la familia de las sulfonamidas, siendo una combinaci\u00f3n de trimetoprima y sulfametoxazol. Los inhibidores de la enzima convertidora de angiotensina (IECAs) y los antagonistas de los receptores de angiotensina II (ARA II), son f\u00e1rmacos utilizados habitualmente para el tratamiento de la hipertensi\u00f3n arterial. Act\u00faan bloqueando a distinto nivel [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Farmacia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FarmaciaUCH\" \/>\n<meta property=\"article:published_time\" content=\"2015-08-18T09:13:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-02-21T14:10:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\" \/>\n\t<meta property=\"og:image:width\" content=\"566\" \/>\n\t<meta property=\"og:image:height\" content=\"424\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Universidad CEU Cardenal Herrera\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Universidad CEU Cardenal Herrera\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\"},\"author\":{\"name\":\"Universidad CEU Cardenal Herrera\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\"},\"headline\":\"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.\",\"datePublished\":\"2015-08-18T09:13:29+00:00\",\"dateModified\":\"2020-02-21T14:10:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\"},\"wordCount\":172,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\",\"keywords\":[\"farmacolog\u00eda\",\"historias de medicamentos\",\"innovaciones terap\u00e9uticas\",\"laboratorio\",\"salud p\u00fablica\"],\"articleSection\":[\"Divulgaci\u00f3n Cient\u00edfica\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\",\"name\":\"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\",\"datePublished\":\"2015-08-18T09:13:29+00:00\",\"dateModified\":\"2020-02-21T14:10:30+00:00\",\"author\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\"},\"breadcrumb\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\",\"contentUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png\",\"width\":566,\"height\":424},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Divulgaci\u00f3n Cient\u00edfica\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/\",\"name\":\"Blog de Farmacia\",\"description\":\"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\",\"name\":\"Universidad CEU Cardenal Herrera\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g\",\"caption\":\"Universidad CEU Cardenal Herrera\"},\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/author\/sgomez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/","og_locale":"es_ES","og_type":"article","og_title":"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.","og_description":"Cotrimoxazol es un antimicrobiano que pertenece a la familia de las sulfonamidas, siendo una combinaci\u00f3n de trimetoprima y sulfametoxazol. Los inhibidores de la enzima convertidora de angiotensina (IECAs) y los antagonistas de los receptores de angiotensina II (ARA II), son f\u00e1rmacos utilizados habitualmente para el tratamiento de la hipertensi\u00f3n arterial. Act\u00faan bloqueando a distinto nivel [&hellip;]","og_url":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/","og_site_name":"Blog de Farmacia","article_publisher":"https:\/\/www.facebook.com\/FarmaciaUCH","article_published_time":"2015-08-18T09:13:29+00:00","article_modified_time":"2020-02-21T14:10:30+00:00","og_image":[{"width":566,"height":424,"url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png","type":"image\/png"}],"author":"Universidad CEU Cardenal Herrera","twitter_misc":{"Escrito por":"Universidad CEU Cardenal Herrera","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#article","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/"},"author":{"name":"Universidad CEU Cardenal Herrera","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64"},"headline":"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.","datePublished":"2015-08-18T09:13:29+00:00","dateModified":"2020-02-21T14:10:30+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/"},"wordCount":172,"commentCount":0,"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png","keywords":["farmacolog\u00eda","historias de medicamentos","innovaciones terap\u00e9uticas","laboratorio","salud p\u00fablica"],"articleSection":["Divulgaci\u00f3n Cient\u00edfica"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/","url":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/","name":"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves.","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage"},"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png","datePublished":"2015-08-18T09:13:29+00:00","dateModified":"2020-02-21T14:10:30+00:00","author":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64"},"breadcrumb":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#primaryimage","url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png","contentUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/07\/10-072.png","width":566,"height":424},{"@type":"BreadcrumbList","@id":"https:\/\/blog.uchceu.es\/farmacia\/combinaciones-de-cotrimoxazol-y-antihipertensivos-ieca-ara-ii-potencian-el-riesgo-de-reacciones-adversas-graves\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/blog.uchceu.es\/farmacia\/"},{"@type":"ListItem","position":2,"name":"Divulgaci\u00f3n Cient\u00edfica","item":"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/"},{"@type":"ListItem","position":3,"name":"Combinaciones de cotrimoxazol y antihipertensivos (IECA, ARA-II) potencian el riesgo de reacciones adversas graves."}]},{"@type":"WebSite","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website","url":"https:\/\/blog.uchceu.es\/farmacia\/en\/","name":"Blog de Farmacia","description":"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64","name":"Universidad CEU Cardenal Herrera","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g","caption":"Universidad CEU Cardenal Herrera"},"url":"https:\/\/blog.uchceu.es\/farmacia\/author\/sgomez\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/users\/362"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/comments?post=2171"}],"version-history":[{"count":0,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2171\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media\/2172"}],"wp:attachment":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media?parent=2171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/categories?post=2171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/tags?post=2171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}